Biote Corp. (BTMD) Stock Price & Analysis
Biote Corp. (BTMD) fell 5.56% to USD 2.21 as of June 10, 2026 at 07:08 UTC, according to Nexqual real-time market data.
BTMD last closed at USD 2.34; the session ranged USD 2.17–2.43 on volume of 482,779 shares. Market capitalization is $78.57M, with a 52-week range of USD 1.27–4.75 (NGM). Source: Nexqual, June 10, 2026 at 07:08 UTC.
Key Statistics (as of June 10, 2026 at 07:08 UTC)
| Price | USD 2.21 |
|---|---|
| Change | ▼ 5.56% (down) |
| Previous Close | USD 2.34 |
| Open | USD 2.37 |
| Day Range | USD 2.17 – 2.43 |
| 52-Week Range | USD 1.27 – 4.75 |
| Volume | 482,779 shares |
| Market Cap | $78.57M |
| Exchange | NGM |
Technical Analysis (BTMD)
Nexqual's technical model rates BTMD "BUY" based on 5 bullish and 1 bearish signals across 123 daily candles, as of June 10, 2026 at 07:08 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 61.88 (neutral) |
| vs SMA50 | Above (USD 1.99) |
| MACD | 0.07 (positive) |
Analyst Ratings (BTMD)
Wall Street analysts rate BTMD "Strong Buy" based on 5 analysts, with a mean price target of USD 2.99 (range USD 2–4), per Nexqual as of June 10, 2026 at 07:08 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 2.99 |
| High Target | USD 4 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 4 / 1 / 0 |
Earnings (BTMD)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 0.08 |
| Revenue Estimate | $46.15M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.08 vs est 0.08 ▼ miss |
| 2025-12-31 | USD 0.07 vs est 0.1 ▼ miss |
| 2025-09-30 | USD 0.18 vs est 0.12 ▲ beat |
| 2025-06-30 | USD 0.16 vs est 0.13 ▲ beat |
Source: Nexqual, June 10, 2026 at 07:08 UTC.
Financials & Fundamentals (BTMD)
| Total Revenue | $188.16M |
|---|---|
| Revenue Growth (YoY) | -8.30% |
| Gross Margin | +70.12% |
| Operating Margin | +9.78% |
| Profit Margin | +8.29% |
| Current Ratio | 1.29 |
| Total Cash | $5.32M |
| Total Debt | $108.42M |
| Free Cash Flow | $-4.73M |
Source: Nexqual, June 10, 2026 at 07:08 UTC.
Financial Health Score (BTMD)
Nexqual rates Biote Corp.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 07:08 UTC.
| Growth | Weak — Revenue -3% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 70%, operating 10% |
| Balance Sheet | Mixed — $5M cash vs $108M debt |
| Cash Flow | Weak — FCF negative: -$5M, burning cash |
| Efficiency | Mixed — No data |
Ownership (BTMD)
| Insider Ownership | +10.39% |
|---|---|
| Institutional Ownership | +66.60% |
| Shares Outstanding | 30.33M |
| Float | 19.62M |
| Short % of Float | +6.42% |
Source: Nexqual, June 10, 2026 at 07:08 UTC.
Leadership (BTMD)
Biote Corp. is led by Joel Pickering, Chief Marketing Officer, per Nexqual as of June 10, 2026 at 07:08 UTC.
| Chief Marketing Officer | Joel Pickering |
|---|
Major Backers & Investors (BTMD)
Notable institutional backers of Biote Corp. include 325 Capital Llc, Bandera Partners LLC, Acadian Asset Management. LLC, according to Nexqual as of June 10, 2026 at 07:08 UTC.
Active Investors
| Investor | Stake |
|---|---|
| 325 Capital Llc | 14.32% |
| Bandera Partners LLC | 6.51% |
| Acadian Asset Management. LLC | 2.2% |
| Fidelity | 1.27% |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Small Cap Portfolio | 0.93% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.11% |
| Vanguard Group | 7.36% |
| State Street | 2.04% |
| Geode Capital | 1.94% |
| Dimensional Fund Advisors | 1.71% |
Source: Nexqual, June 10, 2026 at 07:08 UTC.
From Biote Corp.'s Latest SEC 10-K Filing (filed 2026-03-13)
Key Strengths & Strategy (as disclosed to the SEC)
- biote Corp. operates in practice-building business within the hormone optimization space.
- It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance.
- It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CCSI | Consensus Cloud Solutions, Inc. | USD 34.22 | ▲ 2.15% |
| TRDA | Entrada Therapeutics, Inc. | USD 6.37 | ▲ 0% |
| DCGO | DocGo Inc. | USD 0.58 | ▲ 3.6% |
| AVAH | Aveanna Healthcare Holdings Inc | USD 6.87 | ▲ 2.84% |
| AIRS | AirSculpt Technologies, Inc. | USD 5.28 | ▲ 3.33% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:08 UTC. This page is informational and not investment advice.